PlumX Metrics
Embed PlumX Metrics

Recently discovered EZH2 and EHMT2 (G9a) inhibitors

Future Medicinal Chemistry, ISSN: 1756-8927, Vol: 8, Issue: 13, Page: 1635-1654
2016
  • 27
    Citations
  • 0
    Usage
  • 26
    Captures
  • 0
    Mentions
  • 0
    Social Media
Metric Options:   Counts1 Year3 Year

Metrics Details

Review Description

Methyltransferase enzymes are promising epigenetic oncotargets. Recent efforts toward the development of inhibitors of two methyltransferases, EZH2 and G9a, as potential anticancer therapies are reviewed with a focus on the structure-activity relationships of compounds published from 2012. Benzamide-substituted 2-pyridones are still by far the most popular selective EZH2 inhibitor class but alternative classes are now being reported. There are now three EZH2 inhibitors in clinical development with the first responses in lymphoma patients with tazemetostat. Potent inhibitors of G9a are also published but no examples have yet reached the clinic. Dual blockage of EZH2-G9a is exemplified by one series of compounds. We conclude this review by presenting the three clinical stage compounds with the first clinical response data.

Bibliographic Details

Soumyanarayanan, Uttara; Dymock, Brian W

Informa UK Limited

Biochemistry, Genetics and Molecular Biology; Pharmacology, Toxicology and Pharmaceutics

Provide Feedback

Have ideas for a new metric? Would you like to see something else here?Let us know